Human mesenchymal stem cells alter the gene profile of monocytes from patients with Type 2 diabetes and end-stage renal disease.
AIM
Macrophage infiltration contributes to the pathogenesis of Type 2 diabetes. Mesenchymal stem cells (MSCs) possess immunomodulatory properties, making them an ideal candidate for therapeutic intervention. This study investigated whether MSCs can modulate the phenotype of monocytes isolated from Type 2 diabetic patients with end-stage renal disease.


MATERIALS & METHODS
Monocytes from control (n = 4) and Type 2 diabetic patients with end-stage renal disease (n = 5) were assessed using flow cytometry and microarray profiling, following 48 h of co-culture with MSCs.


RESULTS
Control subjects had a greater proportion of CD14(++)CD16(-) monocytes while diabetic patients had a higher proportion of CD14(++)CD16(+) and CD14(+)CD16(++) monocytes. MSCs promoted the proliferation of monocytes isolated from diabetic patients, reduced HLA-DR expression in both groups and promoted the expression of anti-inflammatory genes.


CONCLUSION
MSC-derived factors alter the polarization of monocytes isolated from healthy and diabetic subjects toward an M2 phenotype.
['Wise|Andrea F|AF|', 'Williams|Timothy M|TM|', 'Rudd|Stephen|S|', 'Wells|Christine A|CA|', 'Kerr|Peter G|PG|', 'Ricardo|Sharon D|SD|']
D000328:Adult D000368:Aged D000369:Aged, 80 and over D018920:Coculture Techniques D003924:Diabetes Mellitus, Type 2 D005260:Female D020869:Gene Expression Profiling D005786:Gene Expression Regulation D006801:Humans D007676:Kidney Failure, Chronic D008297:Male D059630:Mesenchymal Stem Cells D008875:Middle Aged D009000:Monocytes
mesenchymal stem cells monocytes Type 2 diabetes end-stage renal disease macrophages